Business in Brief

No major side effects for Teva after Copaxone patent loss; Mivtach Shamir opens talks with Bright Food over possible Tnuva deal, Castro profits slump and tech shares lead TASE above 1,400 points.

comments Print

Mild market reaction as Teva loses Copaxone patent